Chronic urticaria, characterized by recurrent and persistent hives and itching, poses significant challenges in terms of effective treatment options. Omalizumab, a monoclonal antibody targeting Immunoglobulin E (IgE), has shown promising results in managing chronic urticaria; however, not all patients respond equally to this therapy. The advent of precision medicine has opened up new avenues for tailoring treatment approaches based on individual patient characteristics and biomarker analysis. This review explores the capability of biomarkers in evaluating the treatment response to omalizumab in chronic urticaria. Several potential biomarkers, including serum levels of IgE, IgE autoantibodies, and various inflammatory mediators, have been investigated as indicators of treatment response. By analyzing these biomarkers, clinicians can gain valuable insights into the underlying mechanisms of chronic urticaria and predict the likelihood of response to omalizumab therapy.
HTML PDFShare this article
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
